



C2C BUSINESS STRATEGIES LLC

Financial Research & Publications Group

Specializing in Comprehensive Financial Reports for Public and Private
Lower Middle Market Companies

Strategic Risk & Opportunity Assessment Report



Endo Inc. (OTC: NDOI)

Prepared by:
C2C Business Strategies LLC
Date: July 2025

Safe Harbor Statement

The business reviews presented by C2C Business Strategies, LLC may contain forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements.

Disclaimer

This business review is **NOT** a solicitation to buy or sell any security. It is provided solely for informational purposes. The content reflects facts, views, opinions, and recommendations from individuals and organizations both related and unrelated to C2C Business Strategies, LLC. C2C Business Strategies LLC does not guarantee the accuracy, completeness, or timeliness of any information presented, nor does it endorse any views, opinions, or recommendations contained herein, or provide investment advice.

C2C Business Strategies, LLC's mission is to provide and disseminate useful information on small public & private companies through business reviews and summaries. This information is intended for educational and informational purposes only and should not be construed as investment advice or an endorsement of any company discussed.

C2C Business Strategies LLC has not received compensation for this business review and does not anticipate any such compensation from the subject company or its affiliates. The business review is made available to the public via C2C Business Strategies, LLC's electronic distribution.

Investment Risk Notice:

Investments in small-cap companies involve a high degree of risk, which can vary significantly

1. Executive Summary

Endo, Inc. (OTC: NDOI) is a diversified pharmaceutical company headquartered in Malvern, Pennsylvania.¹ In April 2024, Endo emerged from Chapter 11 bankruptcy proceedings, significantly reducing its debt and resolving numerous opioid-related lawsuits.¹ The company now operates with a strengthened balance sheet and a renewed focus on delivering life-enhancing therapies.¹ Endo's portfolio spans four primary segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals.¹ The planned merger with Mallinckrodt, valued at \$6.7 billion, further strengthens its market positioning and is expected to create a global, scaled, diversified pharmaceuticals leader.¹

In Q4 2024, Endo reported \$467 million in revenue, a 6% decrease compared to Q4 2023, and a net loss of \$(349) million, though Adjusted Net Income was \$70 million and Adjusted EBITDA was \$164 million.¹ For the full year 2024, total revenues were \$1.178 billion (Successor period) and \$582 million (Predecessor period), compared to \$2.011 billion in 2023, primarily due to competitive pressures.⁴ The company projects 2025 revenue guidance of \$1.775 billion to \$1.860 billion and adjusted EBITDA guidance of \$620 million to \$650 million, representing a return to growth.⁵ Endo's strategic focus is on leveraging merger synergies, expanding specialty and injectable product lines, strengthening compliance, and driving international market entry to achieve operational stability and long-term value creation.¹

2. Company Overview

Endo, Inc. is a diversified pharmaceutical company publicly traded on the OTC market under the ticker NDOI.¹ Its headquarters are located in Malvern, Pennsylvania, USA.¹ The company's official website is

www.endo.com.¹

Endo's business model is centered on the development and commercialization of branded and generic pharmaceuticals, sterile injectables, and specialty medicines.¹ The company's portfolio is organized into four primary segments:

- **Branded Pharmaceuticals:** Products targeting therapeutic areas such as urology, orthopedics, and endocrinology.¹
- **Sterile Injectables:** Hospital-based, ready-to-use formulations.¹

- **Generic Pharmaceuticals:** Cost-effective, high-quality generic medications.¹
- **International Pharmaceuticals:** Specialty products primarily in Canada, though this segment is planned for divestiture.¹

The company serves key markets in the United States and internationally.¹ As of December 31, 2024, Endo had 3,116 employees globally, an increase of 6.31% from the previous year.⁹

Endo's history dates back to 1920 when Intravenous Products of America, Inc. was founded in New York City.¹⁰ The company later changed its name to Endo Products in 1935.¹⁰ In 1970, E.I. du Pont de Nemours & Company (DuPont) acquired Endo.¹⁰ In 1990, DuPont and Merck created The DuPont Merck Pharmaceuticals Company, which reestablished Endo as a separate generic division, Endo Laboratories LLC, in 1993.¹⁰ In 1997, three executives from DuPont Merck, led by Carol Ammon, acquired 37 pharmaceutical products and the Endo name to form Endo Pharmaceuticals Inc., which became a publicly traded company in July 2000.¹⁰ In April 2024, Endo emerged from Chapter 11 bankruptcy proceedings, significantly reducing its debt and resolving numerous opioid-related lawsuits, and acquired substantially all of the assets of Endo International plc.¹ The company is now focused on growth and operational efficiency post-reorganization.¹

Key Company Information

Attribute	Detail
Legal Name	Endo, Inc. ¹
Headquarters	Malvern, Pennsylvania, USA ¹
Website	www.endo.com ¹
Ticker	NDOI (OTC) ¹
Founded	1920 (as Intravenous Products of America, Inc.) ¹⁰

Incorporated	1997 (as Endo Pharmaceuticals Inc.) ¹⁰
Industry	Pharmaceuticals ¹
Business Model	Development and commercialization of branded and generic pharmaceuticals, sterile injectables, and specialty medicines ¹
Total Employees	3,116 (as of Dec 31, 2024) ⁹
Key Markets	United States and international markets (primarily Canada for International Pharma) ¹

3. Leadership and Founding Team

Endo, Inc. is led by an executive team with diverse experience in the pharmaceutical and life science industries, overseen by a Board of Directors.

- **Blaise Coleman:** Serves as President and Chief Executive Officer (CEO) and a Board Member. Appointed CEO in February 2022, Mr. Coleman previously held roles as Executive Vice President & CFO and Senior Vice President Global Finance Operations at Endo. Prior to joining Endo in January 2015, he held finance leadership roles with AstraZeneca (including CFO, U.S. Diabetes Business) and Centocor (a Johnson & Johnson subsidiary). He is a Certified Public Accountant with an MBA from Duke University's Fuqua School of Business and a B.S. in Accounting from Widener University. He led a multiyear transformation plan for Endo, including operational improvements and the Chapter 11 restructuring.¹
- **Scott Hirsch:** Serves as Interim CEO.¹⁸
- **Mark Bradley:** Executive Vice President and Chief Financial Officer.¹⁸
- **Matthew J. Maletta:** Executive Vice President, Chief Legal Officer and Secretary.¹⁸
- **Mick McGuinness:** Senior Vice President, Global Head of Quality and Compliance.¹⁸
- **James Papp:** Head of Endo Ireland and Senior Vice President, Global Supply Chain.¹⁸
- **Laure Park:** Senior Vice President, Investor Relations and Corporate Affairs.¹⁸
- **Michael Randolph:** Senior Vice President, Global Head of Manufacturing Operations.¹⁸
- **Cheryl Stouch:** Senior Vice President, Information Technology and Chief

Information Officer.¹⁸

- **James Tursi:** Executive Vice President, Global Research and Development.¹⁸
- **Susan Williamson:** Senior Vice President and Chief Compliance Officer.¹⁸

The **Board of Directors** provides strategic oversight and governance, with members possessing deep understanding of the pharmaceutical industry and extensive leadership and capital markets experience. Notable board members include Paul Herendeen (Board Chairperson) and Paul Efron.¹⁸

The company's origin dates back to 1920 with Intravenous Products of America, Inc., founded by five brothers in the Ushkow family.¹⁰ The current entity, Endo Pharmaceuticals Inc., was formed in 1997 through a management buyout led by Carol Ammon, Louis Vollmer, and Mariann MacDonald, who acquired 37 pharmaceutical products from DuPont Merck Pharmaceutical Company.¹⁰

The leadership team's collective knowledge and strategic acumen are crucial for guiding Endo's transformation, driving innovation, and delivering sustainable value to stakeholders in a complex and rapidly evolving healthcare landscape.¹⁸

4. Product/Service Portfolio

Endo, Inc. offers a diversified portfolio of pharmaceutical products across several therapeutic areas, leveraging its expertise in branded, generic, and sterile injectable medicines.

Core Product Categories and Key Drugs:

- **Branded Pharmaceuticals:** This segment targets specific therapeutic areas including urology, orthopedics, and endocrinology.¹ Key products include:
 - **XIAFLEX®:** Used for Peyronie's disease and other connective tissue disorders. It is the second highest-selling drug in Endo's portfolio, with annual sales significantly contributing to revenue.⁵
 - **SUPPRELIN® LA:** Used to treat central precocious puberty in children.²¹
 - **AVEED®:** An injectable testosterone product.²¹
 - **PERCOCET®:** A combination opioid drug for moderate to severe pain.²¹
 - **TESTOPEL®:** A testosterone pellet for hypogonadism.²¹
 - **EDEX®:** For erectile dysfunction.²¹
 - **QWO®:** An injectable treatment for cellulite.²²
 - **NASCOBAL® Nasal Spray:** For vitamin B12 deficiency.¹⁵
- **Sterile Injectables:** Primarily hospital-based, ready-to-use (RTU) and

ready-to-administer (RTA) formulations, part of their TruDelivery® platform, designed to streamline hospital operations.¹ Key products include:

- **VASOSTRICT®**: An injectable vasopressin used in critical care settings for vasodilatory shock. It has been Endo's top-selling drug, with annual sales approaching \$900 million, making it a market leader in its category.²¹
- **ADRENALIN®**: An epinephrine product, including ready-to-use premixed bags.⁵
- **APLISOL®**: A tuberculin purified protein derivative.²¹
- **Generic Pharmaceuticals**: Offers a diverse portfolio of cost-effective, high-quality generic medications, including a significant contribution from Lidocaine patch 5%.¹
- **International Pharmaceuticals**: Focuses on specialty products, primarily in Canada, though this segment is undergoing divestiture.¹

Dosage Forms and Delivery Methods:

Endo's portfolio encompasses various dosage forms, including oral solutions, tablets, and injectable formulations.²² The company is also exploring novel formulations and delivery systems, such as oral octreotide therapy and polymer-based systems, to enhance bioavailability and patient convenience.²⁵

5. Market Position & Peer Analysis

Endo, Inc. operates as a diversified pharmaceutical company with a post-reorganization focus on growth and operational efficiency.¹ Its market position is characterized by a strong portfolio in branded, generic, and sterile injectable pharmaceuticals.

Market Position:

- **Post-Reorganization Focus**: Having emerged from Chapter 11 bankruptcy, Endo is now operating with a strengthened balance sheet and a renewed focus on delivering life-enhancing therapies and driving growth.¹
- **Leadership in Key Products**: Endo holds market leadership in specific product categories, such as VASOSTRICT® (top-selling drug, market leader in its category) and XIAFLEX® (second highest-selling drug, strong market presence in its niche).²²
- **Diversified Portfolio**: Its four segments (Branded, Sterile Injectables, Generic, International) provide a broad market presence and reduce reliance on a single product or therapeutic area.¹
- **Compliance and Quality**: The company emphasizes operating with integrity and delivering top-quality products and services, which is crucial in the pharmaceutical industry.²⁶

Market Size & Trends:

- **Specialty Generics Market:** This market was valued at \$80.837 billion in 2024 and is projected to reach \$182.082 billion by 2031, growing at a CAGR of 12.3%. The U.S. market alone is projected to reach \$56.809 billion by 2031.²⁷ This growth is driven by:
 - Increasing pressure to contain healthcare costs.
 - Rising prevalence of chronic diseases.
 - Upcoming patent expirations for branded drugs.
 - Regulatory support for faster approvals.²⁷
- **Generic Sterile Injectable Market:** This market surpassed \$46.55 billion in 2024 and is anticipated to reach around \$119.65 billion by 2034, expanding at a CAGR of 9.9%. North America dominated in 2024, with the U.S. market projected to reach \$41.57 billion by 2034.²⁷ Key drivers include:
 - Innovation in drug delivery technology.
 - Growing R&D investment.
 - Rising demand for low-cost treatments and personalized therapies.
 - Expiration of patents for branded injectable drugs.²⁷
- **Shift to Complex Formulations:** A key trend is the shift toward complex formulations and innovative drug delivery systems, including injectables, extended-release forms, and biologics/biosimilars.²⁷

Peer Analysis:

Endo operates in a highly competitive environment with large multinational corporations and specialized niche competitors.²⁴ Key competitors include:

- **Mallinckrodt:** Specializes in pain management solutions and sterile injectable products, presenting direct competition to Endo's core offerings. The planned merger aims to combine strengths.¹
- **Teva Pharmaceuticals:** Known for its strong generics business and aggressive cost-leadership strategies, competing directly in pain management and other therapeutic segments. Teva's global reach and diversified portfolio make it a significant rival in generics.¹
- **Viatis (formerly Mylan Inc.):** A large global producer of generic medicines, competing directly with Teva and Endo on price and manufacturing scale.¹
- **Other Competitors:** Allergan (medical aesthetics, pain management), Johnson & Johnson, Sandoz.²⁴

Competitive Advantages of Endo:

- **Strong Portfolio Post-Reorganization:** A streamlined portfolio with key revenue drivers like XIAFLEX® and VASOSTRICT®.¹
- **Cost-Efficiency & Agile Model:** Known for its agile operational model and cost-competitive production methods, allowing it to challenge larger players.²⁴
- **Expertise in Pain Management & Sterile Injectables:** Recognized for its pain management solutions and strong presence in sterile injectables.²²

Competitive Weaknesses of Endo:

- **Smaller Scale:** Relative to giants like Teva, Endo's smaller scale can make it more vulnerable to demand fluctuations or regulatory changes and may limit R&D capacity.³²
- **Litigation Legacy:** Has faced significant litigation risks, particularly related to opioids, impacting its brand image and financial standing.²⁴
- **Revenue Fluctuations:** Revenue performance, especially in branded and sterile injectables, is susceptible to competitive pressures and market repositioning strategies.⁴

6. Financial Performance, Valuation & Benchmarking

Endo, Inc. (OTC: NDOI) is a publicly traded company, and its recent financial performance reflects the impact of its Chapter 11 reorganization and ongoing market dynamics.

Financial Performance (Annual, as of December 31):

- **Total Revenues, Net:**
 - FY2024 (Successor): \$1,178.2 million ⁴
 - FY2024 (Predecessor, Jan 1 - Apr 23): \$582.0 million ⁴
 - FY2023: \$2,011.5 million (down 13% YoY) ³⁶
 - FY2022: \$2,318.9 million ³⁶
- **Net Income/(Loss):**
 - FY2024 (Successor): \$(730.9) million ⁴
 - FY2024 (Predecessor, Jan 1 - Apr 23): \$6,190.5 million (due to reorganization items) ⁴
 - FY2023: \$(2,449.8) million ³⁷
 - FY2022: \$(2,923.1) million ³⁷
- **Adjusted EBITDA:**
 - FY2024: \$404.4 million (projected) ¹
 - FY2023: \$761.8 million ³⁷
 - FY2022: \$892.1 million ³⁷

Financial Performance (Quarterly, Q4 2024 and Q1 2025):

- **Q4 2024 Revenue:** \$467 million (down 6% YoY) ¹
- **Q4 2024 Net Loss:** \$(349) million ¹
- **Q4 2024 Adjusted Net Income:** \$70 million ¹
- **Q4 2024 Adjusted EBITDA:** \$164 million ¹

- **Q4 2024 Cash & Equivalents:** \$387 million ¹
- **Q1 2025 Revenue:** \$392.8 million (down from \$419.5 million in Q1 2024) ⁴⁰
- **Q1 2025 Net Loss:** \$(128.6) million (improved from \$(154.2) million in Q1 2024) ⁴⁰
- **Q1 2025 Cash & Equivalents:** \$370 million ⁴⁰
- **Q1 2025 Net Cash Provided by Operating Activities:** \$1.128 million (down from \$25.794 million in Q1 2024) ⁴⁰

Key Observations from Financials:

- Endo emerged from Chapter 11 bankruptcy in April 2024, significantly reducing its debt and resolving opioid-related lawsuits, leading to a strengthened balance sheet. ¹
- The company has experienced revenue declines in recent years, primarily due to competitive pressures in the Generic Pharmaceuticals and Sterile Injectables segments. ⁴
- Despite GAAP net losses, Adjusted Net Income and Adjusted EBITDA show positive figures, indicating underlying operational profitability when non-recurring items are excluded. ¹
- Cash and cash equivalents have fluctuated, with a decrease in Q1 2025 due to interest expense, working capital investment, taxes, and transaction-related expenses. ⁴⁰
- The company's gross margin was 53.0% in 2023, but decreased to -0.5% in the 2024 Successor period due to amortization of inventory step-up, while the Predecessor period had a 55.4% gross margin. ³⁹

Valuation & Benchmarking:

- **Market Capitalization:** Approximately \$1.6 billion (as of July 2025) ²¹
- **P/E Ratio (TTM):** 0.29-0.3x (due to positive EPS, but often infinite due to negative GAAP EPS) ²³
- **EV/EBITDA:** -46.8x (as of July 2025) ⁴⁶
- **Revenue per Employee:** \$556,311 (as of Dec 31, 2024) ⁹ (Another source from 2023 indicates ~\$156,000 ¹)

Benchmarking Context:

- Endo's P/E ratio (when positive) is significantly lower than the peer average (21.7x) and industry average (17.7x), suggesting it might be undervalued based on earnings. ⁴⁶
- The company's valuation reflects its post-bankruptcy status and the ongoing merger with Mallinckrodt, which is expected to create a larger, more diversified entity. ²

7. Mergers & Acquisitions (M&A) and Transactional Activity

Endo, Inc. has undergone significant transactional activity, primarily driven by its Chapter 11 reorganization and a major planned merger, alongside strategic divestitures.

- **Chapter 11 Reorganization (Emergence April 2024):** Endo emerged from Chapter 11 bankruptcy proceedings, which successfully resolved \$8.1 billion in debt and numerous opioid-related lawsuits. This restructuring significantly strengthened its balance sheet and positioned the company for long-term sustainable value creation.¹ As part of this, Endo acquired substantially all of the assets of Endo International plc in April 2024.¹
- **Planned Merger with Mallinckrodt (Announced March 2025):** Endo announced a stock and cash merger with Mallinckrodt plc, valued at an implied pro forma enterprise value of \$6.7 billion. Under the terms, Endo shareholders will receive \$80 million in cash (subject to adjustment) and own 49.9% of the combined company on a pro forma basis. The transaction is expected to close in the second half of 2025, subject to shareholder and regulatory approvals. The combined company is expected to be listed on the New York Stock Exchange.¹
 - **Strategic Rationale:** This merger aims to bring together two highly complementary businesses to broaden patient access and develop new therapies. It is expected to benefit from immediate scale, robust cash flow, and enhanced financial flexibility to invest in internal and external growth opportunities. The combination is projected to generate at least \$150 million of annual operating synergies by Year 3 and approximately \$75 million in Year 1. The companies plan to operationally combine their respective generics businesses and Endo's sterile injectables business, with an intent to separate that combined business at a later date.²
- **Divestiture of International Pharmaceuticals Business (Completed June 2025):** Endo completed the previously announced divestiture of its International Pharmaceuticals business, primarily operated through Canada-based Paladin Pharma Inc., to Knight Therapeutics Inc.⁷ This strategic divestiture will impact future geographical revenue distribution.⁷

These activities collectively demonstrate Endo's aggressive strategy to restructure its financial foundation, expand its core pharmaceutical business through a major merger, and streamline its portfolio through divestitures to focus on key growth areas.

8. SWOT Analysis

A comprehensive SWOT analysis of Endo, Inc. reveals its strategic positioning post-bankruptcy, highlighting its strengths, weaknesses, opportunities, and threats in the pharmaceutical market.

Strengths

- **Strengthened Balance Sheet Post-Bankruptcy:** Emerged from Chapter 11 with significantly reduced debt and resolved opioid-related lawsuits, providing a stronger financial foundation.¹
- **Strong Brand Portfolio & Key Products:** Owns market-leading products like XIAFLEX® and VASOSTRICT®, which are significant revenue drivers and hold strong market positions in their respective categories.⁵
- **Operational Flexibility & Efficiency:** Post-reorganization, the company has enhanced operational efficiency, including cost savings and improved gross margins in certain segments.¹
- **Strategic Merger with Mallinckrodt:** The planned merger is expected to create immediate scale, robust cash flow, and significant annual operating synergies, enhancing market positioning.¹
- **Innovation in Sterile Injectables:** Actively pursuing new product solutions in sterile injectables, with dozens of projects in the pipeline, including ready-to-administer (RTA) and ready-to-use (RTU) medicines (TruDelivery® platform).²⁰

Weaknesses

- **Ongoing Litigation Legacy:** Despite bankruptcy resolution, the company still faces an ongoing litigation legacy, which can impact brand perception and potentially lead to future legal costs.¹
- **Integration Challenges:** The planned merger with Mallinckrodt and past acquisitions may present operational and cultural integration complexities, potentially impacting efficiency and profitability.¹
- **Revenue Decline:** Experienced a decrease in total revenues in 2024 compared to 2023, primarily due to competitive pressures in Generic Pharmaceuticals and

Sterile Injectables.⁴

- **Third-Party Manufacturing Reliance:** Relies on third-party manufacturers for a significant portion of its products, limiting control over manufacturing processes and costs, and posing risks of disruption.⁵⁰
- **Brand Perception:** Highly dependent on market perceptions of its brands; negative publicity could have adverse effects.⁵⁰

Opportunities

- **Mallinckrodt Merger Synergies:** The merger is expected to generate substantial annual operating synergies and provide enhanced financial flexibility for growth investments.¹
- **Expansion in Sterile Injectables & Specialty Generics:** The sterile injectable market is projected to grow significantly (9.9% CAGR), and the specialty generics market (12.3% CAGR) offers substantial growth opportunities, aligning with Endo's product focus.²⁰
- **International Market Entry & Licensing Deals:** Strategic focus on expanding international revenue streams and executing international licensing deals post-merger.¹
- **Biologics & Biosimilars:** Plans to expand into biologics and biosimilars, tapping into a high-growth segment of the pharmaceutical market.¹
- **Technological Advancements:** Leveraging novel formulations, delivery systems (e.g., oral octreotide, TruDelivery® platform), and potentially AI-driven R&D can enhance product efficacy and market positioning.²⁰

Threats

- **Regulatory Compliance Pressures:** Operates in a highly regulated industry with evolving laws and regulations, requiring continuous adaptation and investment to avoid penalties.¹
- **Intense Industry Competition:** Faces fierce competition from larger, well-funded pharmaceutical companies and aggressive generic manufacturers, leading to pricing pressures and market share erosion.¹
- **Product Obsolescence & Generic Entry:** Unpredictable entry of generic competitors can significantly impact revenues, especially for historically high-margin products like VASOSTRICT®.⁷
- **Supply Chain Disruptions:** Vulnerability to disruptions in its complex global supply

chain for raw materials, transportation, and finished goods.²⁶

- **Third-Party Reimbursement Uncertainty:** Price levels may be reduced due to social or political pressures and government efforts to contain healthcare costs, impacting revenue.⁵⁰

9. Customer Segmentation & Deep Dive

Endo, Inc. serves a diverse range of customers within the healthcare ecosystem, primarily categorized by their role in prescribing, purchasing, or consuming pharmaceutical products.

Primary Customer Segments:

- **Healthcare Providers (Physicians & Specialists):** This segment includes specialists such as urologists, orthopedists, and endocrinologists who prescribe Endo's branded and generic medications. They are influenced by product efficacy, safety profiles, clinical data, and patient outcomes.¹
 - *Example:* Sales representatives targeting high-volume opioid prescribers for Opana ER marketing.³⁴
- **Hospitals & Acute Care Settings:** Major purchasers of Endo's sterile injectables, particularly critical care medications like VASOSTRICT®. Hospitals prioritize ready-to-use (RTU) and ready-to-administer (RTA) formulations that streamline operations and support patient care.¹
- **Patients:** The ultimate consumers of Endo's therapies, seeking affordable, high-quality, and life-enhancing medications for various conditions, including pain management, chronic diseases, and specialty conditions.¹
- **Pharmacies & Retailers:** Distribute generic and branded oral medications to patients. They are influenced by pricing, availability, and demand for specific products.
- **Wholesalers & Distributors:** Large partners (e.g., Cencora, Cardinal, McKesson, M&D) who facilitate the broad reach of Endo's products to healthcare providers, hospitals, and pharmacies across the United States and internationally.²⁶
- **International Distributors:** Importers of Endo's specialty products in international markets, primarily Canada for the International Pharmaceuticals segment (though this segment is being divested).¹
- **Government Agencies & Payers:** Influence purchasing decisions through reimbursement policies, formulary inclusions, and healthcare cost containment initiatives.

Customer Needs Addressed:

- **Efficacy & Safety:** Healthcare providers and patients demand products that are clinically effective and safe.²⁰
- **Affordability & Access:** Patients and payers seek cost-effective, high-quality generic alternatives to branded drugs.²⁰
- **Operational Efficiency (for Hospitals):** Hospitals value ready-to-use injectable formulations that simplify administration and reduce preparation time.²⁰
- **Supply Reliability:** All customers require a consistent and reliable supply of essential medicines.²⁶
- **Compliance & Quality Assurance:** Healthcare providers and regulators demand strict adherence to quality standards and regulatory compliance.²⁶

Endo's customer segmentation strategy is to provide tailored solutions across the pharmaceutical value chain, from product development to distribution, to meet the diverse needs of its stakeholders.

10. Sales & Distribution Strategy Analysis

Endo, Inc. employs a multi-faceted sales and distribution strategy that combines direct engagement with healthcare institutions, partnerships with large distributors, and a focus on expanding its international reach post-merger.

Sales Channels:

- **Direct Sales Force:** Endo utilizes a direct sales force to engage with healthcare providers and specialists, particularly for its branded pharmaceuticals targeting specific therapeutic areas (e.g., urology, orthopedics, endocrinology).¹
- **Wholesalers & Distributors:** A significant portion of its products are distributed through major pharmaceutical wholesalers and distributors (e.g., Cencora, Cardinal, McKesson, M&D) to ensure broad market reach to pharmacies, hospitals, and other healthcare institutions.²⁶
- **Hospital Sales:** Direct sales and support to hospitals for its sterile injectables, emphasizing ready-to-use (RTU) and ready-to-administer (RTA) formulations that streamline hospital operations.¹
- **International Distributors:** For its International Pharmaceuticals segment (primarily in Canada), the company relies on international distributors to import and distribute its specialty products.¹

Go-to-Market (GTM) Strategy:

- **Product-Centric Innovation:** The GTM strategy is driven by continuous innovation in product development, particularly in sterile injectables and specialty medicines, to address unmet medical needs and offer differentiated solutions.²⁰
- **Value Proposition:** Emphasizes delivering "life-enhancing therapies" and "essential medicines" that are high-quality and affordable, appealing to both healthcare providers and patients.¹
- **Strategic Partnerships:** Building collaborative and lasting relationships with suppliers (for raw materials, transportation, technology) and large distributors is crucial for operational efficiency and market reach.²⁶
- **Post-Merger Integration:** The planned merger with Mallinckrodt aims to combine their generics businesses and Endo's sterile injectables, with an intent to separate that combined business later. This integration will streamline operations and enhance market positioning.³
- **International Expansion:** A strategic focus on expanding international revenue streams and executing international licensing deals post-merger, moving beyond its U.S.-centric focus.¹
- **Compliance & Quality:** Strict adherence to ethical operations, human rights, labor, health, safety, and environmental standards across its supply chain and product delivery, building trust and ensuring regulatory compliance.²⁶

The multi-channel approach, combined with a strong focus on product innovation, strategic partnerships, and post-merger integration, allows Endo to effectively penetrate its target markets and deliver its diverse product portfolio.

11. Operational Efficiency Metrics

Endo, Inc.'s operational efficiency has been a critical focus, particularly following its Chapter 11 reorganization, with efforts aimed at cost savings and streamlining processes.

Key Operational Observations and Metrics:

- **Gross Margin:** The gross margin was 53.0% in 2023. However, for the Successor year ended December 31, 2024, the gross margin percentage was (0.5)%, primarily due to the impact from amortization of inventory step-up. The Predecessor period (Jan 1 - Apr 23, 2024) had a gross margin of 55.4%.³⁹
- **Operating Margin:** The operating margin was -129.15% as of May 2025 (TTM), indicating significant operating losses.⁵⁴

- **Adjusted EBITDA:** Adjusted EBITDA in Q4 2024 was \$164 million, compared to \$166 million in Q4 2023, showing a slight decrease but remaining positive.¹
- **Cash Flow from Operations:** Net cash provided by operating activities was approximately \$115 million in Q4 2023, compared to \$110 million in Q4 2022. However, in Q1 2025, net cash provided by operating activities was only \$1.128 million, a significant decrease from \$25.794 million in Q1 2024.³⁷
- **Revenue per Employee:** Approximately \$556,311 as of December 31, 2024.⁹ (Another source from 2023 indicates ~\$156,000¹)
- **Inventory Turnover:** The inventory turnover was 2.65 for the trailing twelve months (TTM) as of Q4 2024.⁴³
- **Days Sales in Receivables:** 92.58 days for the most recently reported fiscal quarter (Q1 2025).⁵⁸
- **Cost Savings Initiatives:** Blaise Coleman's leadership led to significant operational improvements resulting in more than \$200 million in annual cost savings.⁶
- **Supply Chain Resilience:** The company focuses on building an inclusive and powerful supply chain by engaging with diverse-owned suppliers, which enhances resilience and supports operational efficiency.²⁶
- **Product Launch Execution:** Focus areas include effective product launch execution, which is critical for converting R&D into revenue efficiently.¹

Overall, Endo is actively working to improve its operational efficiency through strategic cost management, supply chain optimization, and leveraging its post-bankruptcy operational flexibility, despite recent fluctuations in revenue and cash flow.

12. Technology & IP Strategy

Endo, Inc.'s technology and intellectual property (IP) strategy is centered on developing and protecting innovative pharmaceutical and medical therapeutics, with a strong focus on sterile injectables and novel drug delivery systems.

Key Technologies and IP Focus:

- **Sterile Injectable Technologies:** A core area of IP is its expertise in sterile injectables. The company constantly pursues new product solutions for hospitals, with dozens of projects in its pipeline. This includes ready-to-administer (RTA) and ready-to-use (RTU) medicines, part of its TruDelivery® platform, designed to streamline hospital operations and support patient care.¹
- **Novel Formulations & Delivery Systems:** Endo's R&D efforts focus on identifying

opportunities to improve patient outcomes through nonsurgical medicines and innovative drug delivery. This includes research into specific enzymes for connective tissue disorders and the development of oral octreotide therapy with multiple patents dedicated to enhancing bioavailability and optimizing dosing regimens.²⁰

- **Extensive R&D Pipeline:** The company has 40 products in development, with research and development efforts focused on pharmaceutical and medical therapeutics in endocrinology, orthopedics, and urology, as well as sterile injectable and generic medicines.²⁰
- **Biologics and Biosimilars:** Endo plans to expand into biologics and biosimilars, which are complex formulations requiring significant R&D investment and specialized manufacturing capabilities. This represents a strategic move into a high-growth area of the pharmaceutical market.¹
- **Real-World Data Utilization:** The company studies its products post-market using real-world data from medical claims, electronic medical records, and patient surveys to understand product usage and improve patient outcomes.²⁰
- **Quality & Manufacturing Expertise:** Bringing therapeutically equivalent generic products to market requires specialized product design expertise and consistent manufacturing processes, which are key operational IPs.²⁰

IP Protection:

- While one 2020 SEC filing states "Patents: None", other sources indicate that Amryt Endo, Inc. (an assignee related to Endo) has been very active in developing oral octreotide therapy with multiple patents.²⁵ Additionally, Endo UV Tech, Inc. (a medical device innovator) has secured multiple U.S. patents for UV laser-based medical device innovation.⁶⁰ This suggests a complex IP landscape with proprietary software, formulations, and potentially a growing patent portfolio in specific areas.

Endo's IP strategy is focused on continuous innovation in its core therapeutic areas, leveraging advanced delivery systems, and strategically expanding into new product categories like biologics and biosimilars, while protecting its proprietary knowledge.

13. Risk Heatmap

Endo, Inc. operates in a dynamic and highly regulated pharmaceutical market, facing various inherent risks that could impact its financial performance, operations, and strategic objectives.

Risk Heatmap

Risk Category	Level of Risk	Key Contributing Factors
Financial Solvency	Medium	Persistent GAAP net losses ¹ , negative operating margins ⁵⁴ , and cash used in operating activities in Q1 2025. ⁴⁰
Regulatory Compliance	High	Operates in a highly regulated industry with evolving laws and regulations (e.g., product safety, marketing, pricing, data privacy). ¹ Non-compliance can lead to severe penalties, reputational damage, and operational restrictions.
Market Competition	High	Intense competition from numerous established and emerging pharmaceutical companies (e.g., Teva, Viatris, Mallinckrodt) ¹ , leading to pricing pressures and market share erosion, especially from generic entries.
Operational Integration	Medium	Challenges related to integrating acquired businesses (e.g., assets of Endo International plc) ¹ and the planned merger with

		Mallinckrodt ¹ , potentially impacting efficiency and profitability.
Revenue Volatility	Medium	Experienced revenue declines in recent years due to competitive pressures in Generic Pharmaceuticals and Sterile Injectables segments. ⁴
Supply Chain Disruptions	Medium	Vulnerability to disruptions in its complex global supply chain for raw materials, transportation, and finished goods. ²⁶
Litigation Legacy	Medium	Ongoing litigation legacy, particularly related to opioid lawsuits, can impact brand perception and potentially lead to future legal costs, despite bankruptcy resolution. ¹
Third-Party Reimbursement	Low to Medium	Uncertainty regarding third-party reimbursement for products and potential price reductions due to healthcare cost containment efforts. ⁵⁰

14. Strategic Recommendations

Endo, Inc. is at a critical juncture post-bankruptcy, aiming to solidify its market position and achieve sustainable growth in the pharmaceutical industry.

1. **Accelerate Merger Integration & Synergies:** Prioritize and expedite the operational and cultural integration with Mallinckrodt. Rapidly realize the projected annual operating synergies (at least \$150 million by Year 3) to drive revenue growth, enhance financial flexibility, and optimize the combined portfolio.¹
2. **Expand Specialty & Injectable Product Lines:** Intensify R&D and commercialization efforts in high-growth segments like sterile injectables and specialty generics. Leverage the TruDelivery® platform and pipeline projects to introduce new ready-to-use/administer medicines and novel formulations that address hospital and patient needs.¹

3. **Strengthen Compliance & Governance Frameworks:** Continuously invest in and strengthen compliance teams and governance frameworks. Proactive adherence to evolving regulatory requirements is crucial for mitigating legal risks, maintaining brand reputation, and ensuring market access.¹
4. **Drive International Market Entry & Licensing Deals:** Post-merger, strategically focus on expanding international revenue streams through targeted market entry and licensing deals. This will diversify geographical revenue and reduce reliance on the U.S. market.¹
5. **Optimize Supply Chain Resilience:** Enhance supply chain resilience by diversifying suppliers and implementing robust risk management strategies to mitigate impacts from raw material price volatility and geopolitical events. Continue to engage with suppliers who share ethical and quality commitments.²⁶
6. **Explore Biologics & Biosimilars:** Initiate or accelerate plans to expand into biologics and biosimilars. This long-term strategic move can position Endo in a high-growth, high-value segment of the pharmaceutical market, leveraging its expertise in complex formulations.¹

15. Market Trends & Strategic Outlook, and CEO Strategic Supplement

Endo, Inc. is strategically positioned to capitalize on the growing demand for specialty and generic pharmaceuticals, particularly in the sterile injectables market, following its significant financial restructuring.

Market Trends & Strategic Outlook

The strategic outlook for Endo is largely positive, driven by several key market trends:

- **Growing Specialty Generics Market:** The global specialty generics market is projected for significant growth (12.3% CAGR to \$182.082 billion by 2031), fueled by increasing pressure to contain healthcare costs, rising chronic disease prevalence, and upcoming patent expirations for branded drugs.²⁷
- **Expanding Generic Sterile Injectable Market:** This market is also experiencing robust growth (9.9% CAGR to \$119.65 billion by 2034), driven by innovation in drug delivery technology, increased R&D investment, and demand for low-cost treatments.²⁷

- **Shift to Complex Formulations & Advanced Delivery Systems:** The industry trend towards complex formulations, injectables, extended-release forms, and potentially biologics/biosimilars aligns with Endo's R&D focus and product pipeline.²⁰
- **Healthcare Cost Containment:** Global healthcare systems and insurance providers are increasingly seeking cost-effective alternatives to high-priced branded drugs, creating a favorable environment for generic manufacturers.²⁷
- **Digital Health Integration:** The integration of digital health tools to enhance patient adherence and outcomes is an emerging trend that could influence future product development and service offerings.²⁷

Endo's strategic outlook is to capitalize on these trends by leveraging its strengthened balance sheet, integrating the Mallinckrodt merger, and continuously innovating its product portfolio. The company projects full-year 2025 revenue between \$1.7 billion and \$1.77 billion, and 2026 revenue of \$2.28 billion, with EBITDA margins expected to improve to 18% in 2025 and 22% in 2026.¹ This indicates a clear path towards sustained growth and profitability.

CEO Strategic Supplement (Blaise Coleman's Vision)

Blaise Coleman, President and CEO of Endo, Inc., articulates a strategic vision centered on transforming the company into a vibrant growth entity post-bankruptcy, driven by operational stability, innovation, and strategic expansion.

His leadership philosophy and strategic focus areas include:

- **Achieving Operational Stability & Integration:** The paramount executive focus is on ensuring seamless operational stability and successful integration following the Chapter 11 restructuring and the planned merger with Mallinckrodt. This involves optimizing processes and realizing synergies quickly.¹
- **Driving Innovation in Key Therapeutic Areas:** Coleman is committed to driving innovation, particularly in sterile injectables and specialty medicines. This includes developing new targeted portfolio and capability growth investments, and advancing the TruDelivery® platform to address unmet medical needs.¹
- **Expanding International Revenue Streams:** A key strategic imperative is to expand the company's international revenue streams, leveraging its global reach and exploring new licensing deals to diversify its market presence.¹
- **Strengthening Financial Health & Shareholder Value:** Having successfully executed a voluntary Chapter 11 restructuring to significantly reduce debt, the CEO is focused on maintaining a strengthened balance sheet and positioning Endo for

long-term sustainable value creation for shareholders.⁶

- **Commitment to Compliance & Quality:** He emphasizes a commitment to operating with integrity and delivering top-quality products and services, ensuring strict adherence to regulatory standards and ethical practices across the supply chain.²⁶

In essence, CEO Blaise Coleman's strategic supplement would highlight a commitment to disciplined execution of the post-bankruptcy transformation, leveraging strategic mergers and continuous innovation to establish Endo as a leading specialty pharmaceutical company with a strong presence in injectables and global reach.

Works cited

1. C2C Business Strategies - Endo Inc report (NDOI) (1).pdf
2. Endo \$6.7 billion merger with Mallinckrodt - Davis Polk, accessed July 21, 2025, <https://www.davispolk.com/experience/endo-67-billion-merger-mallinckrodt>
3. Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader, accessed July 21, 2025, <https://investor.endo.com/2025-03-13-Mallinckrodt-and-Endo-to-Combine-to-Create-a-Global,-Scaled,-Diversified-Pharmaceuticals-Leader>
4. Endo Reports Fourth-Quarter and Full-Year 2024 Financial Results - Public now, accessed July 21, 2025, https://docs.publicnow.com/viewDoc.aspx?filename=243341\EXT\2CACAD8A8D4F0845ECF2D4565135C79B3409F215_11998A9ED6CB019B9327BCC16DB7BF91E427C37F.PDF
5. Endo Reports Fourth-Quarter and Full-Year 2024 Financial Results - Mar 13, 2025, accessed July 21, 2025, <https://investor.endo.com/2025-03-13-Endo-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results>
6. Blaise Coleman, MBA | Board Member | Ocugen, Inc., accessed July 21, 2025, <https://ir.ocugen.com/board-member/blaise-coleman/>
7. Endo, Inc. SEC 10-Q Report - TradingView, accessed July 21, 2025, <https://www.tradingview.com/news/tradingview:74728d6c9b36e:0-endo-inc-sec-10-q-report/>
8. Endo Completes International Pharmaceuticals Business Divestiture - Jun 17, 2025, accessed July 21, 2025, <https://investor.endo.com/2025-06-17-Endo-Completes-International-Pharmaceuticals-Business-Divestiture>
9. Endo, Inc. (NDOI) Number of Employees - Stock Analysis, accessed July 21, 2025, <https://stockanalysis.com/quote/otc/NDOI/employees/>
10. Endo International and American Medical Systems - History & Products - Drugwatch.com, accessed July 21, 2025, <https://www.drugwatch.com/manufacturers/endo-american-medical-systems/>
11. History - Endo, accessed July 21, 2025, <https://www.endo.com/company/history/>
12. Endo Pharmaceuticals Holdings Inc. - Encyclopedia.com, accessed July 21, 2025, <https://www.encyclopedia.com/books/politics-and-business-magazines/endo-pharmaceuticals-holdings-inc>
13. Carol A. Ammon - Central Connecticut State University, accessed July 21, 2025, <https://www.ccsu.edu/class/carol-ammon>
14. Carol A. Ammon '73 - Central Connecticut State University, accessed July 21, 2025, <https://www.ccsu.edu/ccsufoundation/carol-ammon-73>
15. ENDO REPORTS SECOND-QUARTER 2024 FINANCIAL RESULTS - Investors, accessed July 21, 2025, <https://investor.endo.com/2024-08-27-ENDO-REPORTS-SECOND-QUARTER-2024-FINANCIAL-RESULTS>
16. Endo Number of Employees 2025-2025 | NDOI - Macrotrends, accessed July 21, 2025, <https://macrotrends.net/stocks/charts/NDOI/endo/number-of-employees>
17. Blaise Coleman | Duke's Fuqua School of Business, accessed July 21, 2025, <https://www.fuqua.duke.edu/student-network/alumni-ambassadors/blaise-coleman>

18. Leadership - Endo, accessed July 21, 2025, <https://www.endo.com/company/leadership/>
19. Board of Directors | Endo, accessed July 21, 2025, <https://www.endo.com/company/leadership/board-of-directors/>
20. R&D Approach - Endo, accessed July 21, 2025, <https://www.endo.com/research-and-development/rd-approach/>
21. Endo Inc, NDOI:QXR summary - FT.com, accessed July 21, 2025, <https://markets.ft.com/data/equities/tearsheet/summary?s=NDOI:QXR>
22. What are the top-selling drugs of Endo International? - Patsnap Synapse, accessed July 21, 2025, <https://synapse.patsnap.com/article/what-are-the-top-selling-drugs-of-endo-international>
23. Endo International (ENDP) Stock Price, News & Analysis - MarketBeat, accessed July 21, 2025, <https://www.marketbeat.com/stocks/NASDAQ/ENDP/>
24. Who are the main competitors of Endo International? - Patsnap Synapse, accessed July 21, 2025, <https://synapse.patsnap.com/article/who-are-the-main-competitors-of-endo-international>
25. The patent landscape of Octreotide - Patsnap Synapse, accessed July 21, 2025, <https://synapse.patsnap.com/article/the-patent-landscape-of-octreotide>
26. Suppliers - Endo, accessed July 21, 2025, <https://www.endo.com/products-and-capabilities/suppliers/>
27. Specialty Generics Market Size, Share, Growth Insights 2031, accessed July 21, 2025, <https://www.precisionbusinessinsights.com/market-reports/specialty-generics-market>
28. The Growing Importance of Specialty Generics in the Pharmaceutical Market, accessed July 21, 2025, <https://www.drugpatentwatch.com/blog/the-growing-importance-of-specialty-generics-in-the-pharmaceutical-market/>
29. Generic Sterile Injectable Market Size to Reach USD 119.65 Bn by 2034 High Demand for Low-cost Treatments and Chronic Disease Prevalence - BioSpace, accessed July 21, 2025, <https://www.biospace.com/press-releases/generic-sterile-injectable-market-size-to-reach-usd-119-65-bn-by-2034-high-demand-for-low-cost-treatments-and-chronic-disease-prevalence>
30. Who are the main competitors of Mallinckrodt? - Patsnap Synapse, accessed July 21, 2025, <https://synapse.patsnap.com/article/who-are-the-main-competitors-of-mallinckrodt>
31. Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader, accessed July 21, 2025, <https://ir.mallinckrodt.com/news-releases/news-release-details/mallinckrodt-and-endo-shareholders-approve-combination-create/>
32. Who are the main competitors of Teva? - Patsnap Synapse, accessed July 21, 2025, <https://synapse.patsnap.com/article/who-are-the-main-competitors-of-teva>
33. Endo Pharmaceuticals vs Mallinckrodt - Comparably, accessed July 21, 2025, <https://www.comparably.com/competitors/endo-pharmaceuticals-vs-mallinckrodt>
34. Opioid Manufacturer Endo Health Solutions Inc. Agrees to Global Resolution of

- Criminal and Civil Investigations into Sales and Marketing of Branded Opioid Drug - Department of Justice, accessed July 21, 2025, <https://www.justice.gov/archives/opa/pr/opioid-manufacturer-endo-health-solutions-inc-agrees-global-resolution-criminal-and-civil>
35. Endo Reports Fourth-Quarter and Full-Year 2024 Financial Results - PR Newswire, accessed July 21, 2025, <https://www.prnewswire.com/news-releases/endo-reports-fourth-quarter-and-full-year-2024-financial-results-302400716.html>
 36. Endo International (ENDPQ) - Revenue - Companies Market Cap, accessed July 21, 2025, <https://companiesmarketcap.com/endo-international/revenue/>
 37. ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS - Mar 6, 2024, accessed July 21, 2025, <https://investor.endo.com/2024-03-06-ENDO-REPORTS-FOURTH-QUARTER-2023-FINANCIAL-RESULTS>
 38. ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS - PR Newswire, accessed July 21, 2025, <https://www.prnewswire.com/news-releases/endo-reports-fourth-quarter-2023-financial-results-302081855.html>
 39. Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) - Public now, accessed July 21, 2025, <https://www.publicnow.com/view/090CF955A72E06F7ADAC4A57A889695015CCB6B4>
 40. Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance, accessed July 21, 2025, <https://investor.endo.com/2025-05-07-Endo-Reports-First-Quarter-2025-Financial-Results-and-Reaffirms-2025-Financial-Guidance>
 41. Endo Market Cap 2024-2025 | NDOI - Macrotrends, accessed July 21, 2025, <https://macrotrends.net/stocks/charts/NDOI/endo/market-cap>
 42. Endo PE Ratio 2024-2025 | NDOI - Macrotrends, accessed July 21, 2025, <https://www.macrotrends.net/stocks/charts/NDOI/endo/pe-ratio>
 43. Ratios - Investor and Media Overview | Endo International plc, accessed July 21, 2025, <https://endopharmaceuticalsinc.gcs-web.com/financial-information/fundamentals/ratios>
 44. Endo International plc (ENDP) Stock Price Today - Value Research, accessed July 21, 2025, <https://www.valueresearchonline.com/stocks/99604/endo-international-plc-endp/>
 45. Endo Inc Stock Price Today | OTC: NDOI Live - Investing.com, accessed July 21, 2025, <https://www.investing.com/equities/endo-inc>
 46. Endo (OTCPK:NDOI) Stock Valuation, Peer Comparison & Price Targets - Simply Wall St, accessed July 21, 2025, <https://simplywall.st/en/stocks/us/pharmaceuticals-biotech/otc-ndoi/endo/valuation>
 47. Pipeline - Endo, accessed July 21, 2025, <https://www.endo.com/research-and-development/pipeline/>
 48. Q2 2018 Earnings Report - Investor and Media Overview | Endo International plc, accessed July 21, 2025, <https://endopharmaceuticalsinc.gcs-web.com/static-files/84b9e6fe-cba1-40f6-a447-dcac63eeea8f>

49. RISK FACTORS FOR THE OCCURRENCE AND DEVELOPMENT OF ENDO-PERIODONTAL LESIONS. A REVIEW. - Romanian Journal of Medical and Dental Education, accessed July 21, 2025,
<https://journal.adre.ro/wp-content/uploads/2019/12/RISK-FACTORS-FOR-THE-OCCURRENCE-AND-DEVELOPMENT-OF-ENDO-PERIODONTAL-LESIONS.pdf>
50. Endo, Inc. SEC 10-K Report - TradingView, accessed July 21, 2025,
<https://www.tradingview.com/news/tradingview:281c2673b1aa0:0-endo-inc-sec-10-k-report/>
51. Supplier Diversity: Powering Success and Opportunities - Endo, accessed July 21, 2025,
<https://www.endo.com/newsroom/stories/supplier-diversity-powering-success-and-opportunities/>
52. Endo Inc (NDOI) Announces Upcoming Second Quarter 2025 Financial Results Release, accessed July 21, 2025,
<https://www.gurufocus.com/news/2990484/endo-inc-ndoi-announces-upcoming-second-quarter-2025-financial-results-release-ndoi-stock-news>
53. Products | Endo, accessed July 21, 2025,
<https://www.endo.com/products-and-capabilities/products/>
54. Endo International (ENDPQ) - Operating Margin - Companies Market Cap, accessed July 21, 2025,
<https://companiesmarketcap.com/sgd/endo-international/operating-margin/>
55. Endo, Inc. Cash Flow – OTC:NDOI - TradingView, accessed July 21, 2025,
<https://www.tradingview.com/symbols/OTC-NDOI/financials-cash-flow/>
56. Endo, Inc. (NDOI) Cash Flow Statement - Stock Analysis, accessed July 21, 2025,
<https://stockanalysis.com/quote/otc/NDOI/financials/cash-flow-statement/>
57. 40+ Top Operational KPIs & Metrics for Reporting & More - insightsoftware, accessed July 21, 2025,
<https://insightsoftware.com/blog/35-operational-kpis-and-metric-examples/>
58. Endo, Inc. (NDOI) - Days Sales in Receivables (Quarterly) - AlphaQuery, accessed July 21, 2025,
<https://www.alphaquery.com/stock/NDOI/fundamentals/quarterly/days-sales-receivables>
59. Patents Assigned to AMRYT ENDO, INC., accessed July 21, 2025,
<https://patents.justia.com/assignee/amryt-endo-inc>
60. Endo UV Tech, Inc. Secures fourth U.S. Patent for UV Laser-Based Medical Device Innovation - PharmiWeb.com, accessed July 21, 2025,
<https://www.pharmiweb.com/press-release/2025-07-21/endo-uv-tech-inc-secures-fourth-us-patent-for-uv-laser-based-medical-device-innovation>
61. Patent Portfolio - EndoUVTech, accessed July 21, 2025,
<https://endouvtech.com/global-patents/>

Introduction to the Publisher

C2C Business Strategies Financial Publishing & Research Group:

C2C Business Strategies actively monitors hundreds of lower middle market companies. This includes privately held companies and publicly traded companies across NYSE, NASDAQ, and OTC Markets. Through periodic Strategic Financial & Operational Analysis Reports, we highlight emerging opportunities—while also identifying material risks that could impact performance, valuation, or investor confidence. These insights help stakeholders better understand both the upside potential and the structural vulnerabilities of public micro- and small-cap enterprises.

We specialize in comprehensive financial reports for public and private lower middle market companies, providing detailed, customized financial analysis and reporting for businesses typically generating between \$5 million and \$50 million in annual revenue. These companies occupy a unique space: larger than small businesses, yet not quite large corporations. They often face distinct financial challenges and opportunities. For public companies in this segment, financial reporting must meet strict regulatory standards, ensuring transparency and accuracy for stakeholders and regulators. Private companies, while not subject to the same public scrutiny, still require robust financial reports to inform management decisions, attract investors, and support growth strategies. By focusing on the lower middle market, our expertise ensures that both public and private companies receive the high-quality, actionable financial insights needed to drive performance, maintain compliance, and achieve their strategic goals.

Safe Harbor Statement

The business reviews presented by C2C Business Strategies, LLC may contain forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements.

Disclaimer

This business review is **NOT** a solicitation to buy or sell any security. It is provided solely for informational purposes. The content reflects facts, views, opinions, and recommendations from individuals and organizations both related and unrelated to C2C Business Strategies, LLC. C2C Business Strategies LLC does not guarantee the accuracy, completeness, or timeliness of any information presented, nor does it endorse any views, opinions, or recommendations contained herein, or provide investment advice.

C2C Business Strategies, LLC's mission is to provide and disseminate useful information on small public & private companies through business reviews and summaries. This information is intended for educational and informational purposes only and should not be construed as investment advice or an endorsement of any company discussed.

C2C Business Strategies LLC has not received compensation for this business review and does not anticipate any such compensation from the subject company or its affiliates. The business review is made available to the public via C2C Business Strategies, LLC's electronic distribution.

Investment Risk Notice:

Investments in small-cap companies involve a high degree of risk, which can vary significantly